Table 2 Somatic and mental morbidity of short- and long-term cancer survivors
Variables | Short-term survivors (N = 128) | Long-term survivors (N = 206) | p-value* | Effect Size |
|---|---|---|---|---|
Self-rated health | 0.62 | |||
Good health | 59 (47) | 92 (45) | ||
Poor health | 66 (53) | 112 (55) | ||
Functional impairment | ||||
Physical impairment | 16 (13) | 45 (22) | 0.04 | 0.24 |
Mental impairment | 8 (6) | 15 (7) | 0.89 | |
Somatic diseases | ||||
Infarction, angina or stroke | 18 (14) | 26 (13) | 0.96 | |
Diabetes | 5 (4) | 9 (4) | 0.82 | |
Thyroid diseases | 9 (7) | 39 (19) | 0.01 | 0.36 |
Osteoporosis | 3 (2) | 14 (7) | 0.16 | |
Arthritis, arthrosis | 31 (24) | 49 (24) | 0.62 | |
Musculo-skeletal diseases | 18 (14) | 36 (18) | 0.45 | |
≥1 comorbid disease(s) | 57 (45) | 112 (54) | 0.12 | |
Significant somatic symptoms | ||||
Muscular pain and stiffness affect- | ||||
ting daily activities last month | 18 (14) | 48 (23) | 0.05 | |
Gastrointestinal symptoms last year | 11 (9) | 16 (8) | 0.82 | |
Headache last year | 24 (19) | 52 (25) | 0.35 | |
Regular use of medication last year | ||||
Daily use of any medication | 76 (59) | 114 (53) | 0.55 | |
Analgesics | 21 (16) | 31 (15) | 0.83 | |
Psychotropics | 25 (19) | 43 (21) | 0.99 | |
Antihypertensives | 25 (20) | 50 (24) | 0.33 | |
Mental variables | ||||
HADS-Anxiety, mean (SD)a | 4.8 (4.1) | 4.8 (3.7) | 0.78 | |
HADS-Depression, mean (SD) a | 4.1 (3.3) | 4.4 (3.2) | 0.56 | |
Self-esteem score, mean (SD) | 7.9 (2.1) | 7.7 (2.2) | 0.54 | |
Sleeping problems, N (%) | 30 (25) | 59 (32) | 0.33 | |
Alcohol problems, N (%) | 8 (6) | 17 (8) | 0.15 | |
Lifestyle variables | ||||
BMI, mean (SD) | 27.6 (3.8) | 27.6 (4.8) | 0.70 | |
Physical activity, N (%) | ||||
Minimal | 40 (31) | 80 (39) | 0.63 | |
Moderate or more | 88 (69) | 126 (61) | 0.48 | |
Daily smoker | 26 (20) | 55 (27) | 0.38 | |
Framingham risk score | ||||
Framingham sum score, mean (SD) | 16.1 (2.8) | 16.6 (3.0) | 0.15 | |
Framingham risk >20%, N (%) | 69 (54) | 123 (60) | 0.48 |